Extended Data Fig. 4: The effect of different Flu dosing regimens on gene targeting efficiency.
From: Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice
a, Four-week-old mice were treated with various Flu doses, differing in the length of administration, as described in Fig. 2i, as well as injected i.v. with the gene targeting Alb-P2A-hF9 vector (1 × 1011 vg/mouse) on Day 1 of Flu treatment. Plasma hF9 protein levels from the same mice in Fig. 2i were determined via ELISA for a 90-day time course. Data is displayed as the group mean with error bars representing s.d.; n = 4 mice per group. Significance testing was performed by a two-way ANOVA with Dunnett’s multiple comparison test. P-value of the 3-day treatment was .0004 and < .0001 for the 5-day treatment. b, Body weight of mice in each treated group were monitored throughout the time course. Data is displayed as the group mean with error bars representing s.d.; n = 4 mice per group. Statistics were performed by two-way ANOVA. P-value for the 1-day treatment was .001.
